Similar articles

• Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.

  Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD. Desai AS, et al. JAMA Cardiol. 2017 Jan 1;2(1):79-85. doi: 10.1001/jamacardio.2016.4733. JAMA Cardiol. 2017. PMID: 27842179 Clinical Trial.
• Heart failure: Neprilysin inhibition attenuates risk of hyperkalaemia in HFrEF.

  Huynh K. Huynh K. Nat Rev Cardiol. 2017 Jan;14(1):2-3. doi: 10.1038/nrcardio.2016.196. Epub 2016 Dec 1. Nat Rev Cardiol. 2017. PMID: 27905476 No abstract available.
• Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.

  Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Velazquez EJ, et al. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. N Engl J Med. 2019. PMID: 30415601 Clinical Trial.
• Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.

  Hubers SA, Brown NJ. Hubers SA, et al. Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622. Circulation. 2016. PMID: 26976916 Free PMC article. Review.
• Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.

  Marques da Silva P, Aguiar C. Marques da Silva P, et al. Rev Port Cardiol. 2017 Sep;36(9):655-668. doi: 10.1016/j.repc.2016.11.013. Epub 2017 Aug 23. Rev Port Cardiol. 2017. PMID: 28844335 Review. English, Portuguese.